Holen Sie sich die Stockscreener-App
5.38
2.77%
0.145
Handel nachbörslich:
5.38
Schlusskurs vom Vortag:
$5.235
Offen:
$5.25
24-Stunden-Volumen:
2,019
Relative Volume:
0.00
Marktkapitalisierung:
$7.86M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.49M
KGV:
-0.1816
EPS:
-29.6295
Netto-Cashflow:
$-15.24M
1W Leistung:
-7.51%
1M Leistung:
+5.39%
6M Leistung:
+19.29%
1J Leistung:
-23.03%
1-Tages-Spanne:
$5.19
$5.38
1-Wochen-Bereich:
$5.1505
$5.81
52-Wochen-Spanne:
$1.90
$10.59
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Firmenname
Cns Pharmaceuticals Inc
Sektor
Branche
Telefon
1-800-946-9185
Adresse
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
5.38 | 7.41M | 0 | -16.49M | -15.24M | -29.63 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-12-28 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-08-24 | Eingeleitet | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Aktie (CNSP) Neueste Nachrichten
CNS Pharmaceuticals Inc (CNSP) Cash Flow - TradingKey
CNS Pharmaceuticals Inc (CNSP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CNS Pharmaceuticals Inc (CNSP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CNS Pharmaceuticals Inc (CNSP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TradingKey - TradingKey
CNSP|CNS Pharmaceuticals Inc|Price:5.230|Chg%:-0.160 - TradingKey
CNS Pharmaceuticals Inc (CNSP) Valuation: PE, PB & Fair Value Analysis - TradingKey
CNSP|CNS Pharmaceuticals Inc|Price:5.070|Chg%:-0.160 - TradingKey
CNS Pharmaceuticals Inc (CNSP) Institutional Confidence - TradingKey
CNS Pharmaceuticals Inc (CNSP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CNS Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:CNSP - TradingView
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Exploring a 37% Potential Upside in CNS Therapeutics - DirectorsTalk Interviews
CNS Pharmaceuticals Inc (CNSP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CNS Pharmaceuticals(CNSP) Stock Options Chain | Quotes & News - Moomoo
CNS Pharmaceuticals Q1 2026 Earnings: Wider-than-Expected Loss as Pipeline Costs PersistShare Repurchase Impact - DonanımHaber
CNS Pharmaceuticals Q1 2026 Earnings: EPS Misses Estimates as Biotech Focuses on Clinical Milestones - dars.gov.et
CNS Pharmaceuticals Announces Strategic Oncology-Neurology Realignment - TipRanks
CNS Pharmaceuticals posts investor presentation; details $22.5M financing and strategic pivot - TradingView
Strategic pivot at CNS Pharmaceuticals (NASDAQ: CNSP) backed by $22.5M PIPE - Stock Titan
CNS Pharmaceuticals, Inc. Financial Disclosures & Filings - TradingView
CNS Pharmaceuticals Surges 18% as Momentum Builds (CNSP)Algorithmic Stock Picks - dars.gov.et
CNS Pharmaceuticals Q1 2026 Earnings: Wider-than-Expected Loss Underscores Pre-Revenue Stage Pressures - dars.gov.et
Price to earnings forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
Enterprise value to EBIT forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
CNS Pharmaceuticals (CNSP) Dips 4% as Shares Approach Key Support LevelTPO Profile - dars.gov.et
Enterprise value to EBITDA forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
Price to sales forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
Price to book forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
CNS Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:CNSP) - TradingView
BE50 Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
CNSP Forecast — Price Target — Prediction for 2027 - TradingView
CNS Pharmaceuticals (CNSP) Slides 4.7% as Biotech Sentiment Wavers; Support at $3.84 in FocusSwing Entry Signals - dars.gov.et
SK Biopharm taps Insilico in $2.5B AI CNS drug discovery deal - BioWorld News
ChemDiv, Inc. Highlights Successful Deployment of Proprietary CNS Drug Discovery Platform, Advancing Neurodegenerative Programs for Polku Therapeutics and Brenig Therapeutics - PR Newswire
Why did CNSP stock surge 330% today? - MSN
CNS Pharmaceuticals Inc (CNSP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CNS Pharmaceuticals Inc (CNSP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CNS Pharmaceuticals Inc (CNSP) Stock Price, Quote, News & History - Benzinga
CNS Pharmaceuticals (CNSP) Surges 2.45% as Biotech Stock Tests Key ResistanceDark Pool Sentiment - dars.gov.et
CNSP Q1 2026 Earnings: Wider Than Expected Loss, No Revenue Reported; Stock Rises 3.6%Estimate Revision Count - newsline.com
CNS Pharmaceuticals (CNSP) Tests Key Levels After Modest GainBreadth Thrust - newsline.com
What's going on with CNS Pharmaceuticals stock on Wednesday? - MSN
Relmada Therapeutics Appoints CNS Drug Development Veteran - GlobeNewswire
CNS Pharmaceuticals Company Profile & Introduction - Moomoo
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights Oversubscribed $22.5M Financing, Growth Strategy in Investor Presentation - TradingView
CNS Pharmaceuticals Inc. (CNSP) Q1 2026 Earnings: Wider-than-Expected Loss Highlights Cash Burn and Pipeline ChallengesPretax Income Report - newsline.com
CNS Pharmaceuticals Highlights Oversubscribed $22.5 Million Financing and Growth Strategy - citybuzz -
CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment - ACCESS Newswire
Biotech CFO breaks down oversubscribed $22.5M raise and strategy shift - Stock Titan
NRx Pharmaceuticals Closes $22.3 Million Public Offering to Support Growth and Development of CNS Therapeutics - Quiver Quantitative
Finanzdaten der Cns Pharmaceuticals Inc-Aktie (CNSP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.84%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):